Gilead Sciences (GILD) News Today

Gilead Sciences, Inc. (NASDAQ: GILD) shares remain near a 52-week high and well above their 50-day and 200-day moving averages as investors weigh a favorable product pipeline against risks ahead of the company’s third-quarter 2026 earnings report.

• Positive Sentiment: Gilead completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance for public reimbursement of LYVDELZI (seladelpar), expanding potential access to the treatment for primary biliary cholangitis. The agreement could support adoption and add a new commercial opportunity, although the near-term financial contribution is not yet clear. Gilead Reaches Canadian Reimbursement Deal for Liver Disease Drug Lyvdelzi
• Positive Sentiment: Analyst commentary highlights strong HIV sales, momentum for the company’s newer HIV-prevention product Yeztugo, and expanding oncology prospects. A new oncology trial is being cited as a potential source of substantial upside, with one analysis characterizing GILD as potentially 50% undervalued if the program succeeds. Gilead Stock Could Be 50% Undervalued on New Oncology Trial News
• Neutral Sentiment: Investors are focused on Gilead’s third-quarter results, scheduled for after the bell Thursday. The earnings preview centers on HIV performance, Yeztugo uptake, pipeline progress, guidance, and cash generation. Results that exceed expectations could reinforce the stock’s momentum, while weak guidance could pressure the shares. Gilead Sciences Q3 2026 Earnings Preview
• Negative Sentiment: Some coverage warns that Gilead is burning through cash quickly and faces competitive pressure, creating execution risks despite its strong HIV franchise and pipeline. ETFs were also reported as net sellers, a potentially modest technical headwind. Three Big Pharma Earnings Reports to Watch